To The Moon

Wall Street capped a wild week with the S&P 500 posting its third-straight winning day, climbing 0.6% to 6,878.49 on soft inflation data that cooled yields to 3.75% and locked Fed cuts at 87% odds – this soft print unleashes risk-on vibes for a potential Santa squeeze to 7,100 if PCE Thursday cools below 2.3%. Tech gains dominated, with Micron rising 10% to $115 on blowout earnings from booming AI market, memory demand tripling from Nvidia's H200 frenzy – Q1 rev $9.05B up 18% crushes, unlocking $130 highs as semis rebound from last week's wreck. Tesla jumped about 1% to $446.74, riding $3T valuation buzz on Optimus ramps and FSD v14 boosting ARPU 10%, while Nvidia surged 3% to $140.50 on open-source AI models adding $5B ecosystem rev by 2027. Broadcom gained over 2% to $159.10 on inter

🟩 Is your portfolio ready for the "Strategic Divergence" coming in 2026? While the markets are quiet for the holidays, massive moves are happening under the hood that could redefine your dividend income next year. A surprising beat in US GDP—hitting 4.3% against expectations—is threatening to keep interest rates "Higher for Longer," putting immediate pressure on Singapore REITs and mortgage holders just as we head into the new year. In this special Christmas Eve breakdown, we unwrap three critical stories reshaping the SGX landscape. We analyze Sembcorp’s bold but debt-heavy acquisition in Australia, dissect why City Developments Limited (CDL) suddenly popped 6% in a sleepy market, and expose the "Valley of Death" cash flow trap facing Genting Singapore. Plus, we reveal why major analysts

From my perspective, confirmation that NVIDIA plans to resume H200 deliveries to China around mid-February 2026 is a meaningful near-term catalyst. The expected 5,000–10,000 module sets—equivalent to roughly 40,000–80,000 H200 chips—won't redefine NVIDIA's global revenue base on their own, but they clearly help stabilize expectations around China exposure. After months of uncertainty driven by export controls, even partial normalization reduces downside risk and improves visibility, which explains why the stock reacted positively with a 3% gain. That said, I see the China H200 story more as a confidence booster than a structural growth re-acceleration. The volume involved is material, but not transformative compared with hyperscaler demand in the US, Middle East, and Europe. What matters m

From my perspective, the approval of oral Wegovy is the most important positive catalyst Novo Nordisk has seen this year. A pill form fundamentally lowers the barrier to adoption versus injections, especially for primary care patients and long-term weight management. The market's 7% reaction makes sense to me, because this isn't just a line extension—it meaningfully expands the addressable market and strengthens Novo's positioning in the obesity franchise. That said, I also understand why NVO is still down 38% year to date while Eli Lilly keeps making new highs. Lilly has clearly won the narrative this year, with faster innovation cycles, stronger momentum in data readouts, and more consistent execution. Novo's drawdown reflects disappointment rather than collapse—its core GLP-1 economics

1. China H200 ship-ups and catalyst potential Plans to begin delivering H200 AI chips to China around mid-February 2026 are now widely reported. Initial shipments are expected to comprise roughly 5,000–10,000 module sets, equivalent to approximately 40,000–80,000 chips, subject to Chinese regulatory approval. The move follows a reversal in U.S. export policy that permits H200 sales to “approved customers” with a 25% revenue share for the U.S. government. These shipments would mark the first major resumption of Nvidia’s AI chip exports to China after prior bans.  From a demand perspective, the China market represents a meaningful addressable opportunity for Nvidia given the scale of AI adoption among hyperscalers and cloud providers there. Analysts estimate H200 sales could add materia

Gold reaching USD 5,000 in 2026 is plausible, but not inevitable. Will gold hit USD 5,000 in 2026? The move towards USD 4,500 suggests gold is already pricing in a combination of policy easing, geopolitical risk and structural demand. Two Fed cuts in 2026 would lower real yields, which is historically supportive for gold. In addition, persistent central bank buying, fiscal deficits and currency debasement concerns provide a strong long-term floor. That said, USD 5,000 likely requires a reinforcing shock, such as a sharper economic slowdown, renewed inflationary pressure, or an escalation in geopolitical conflict. In a benign soft-landing scenario with stable growth and a firm US dollar, gold may consolidate between USD 4,200 and USD 4,700 rather than extend aggressively. How to express the

Novo Nordisk’s rally on approval of an oral Wegovy is strategically important, but it does not automatically guarantee a sustained turnaround. Why the oral approval matters An effective oral GLP-1 materially expands the addressable market. Many patients avoid injectables due to inconvenience or needle aversion, particularly in primary care and early-stage obesity treatment. From a competitive standpoint, this is Novo Nordisk’s first credible answer to Eli Lilly’s strong pipeline momentum and helps rebalance the narrative that NVO is structurally losing ground. Why NVO underperformed so sharply NVO’s 38% decline this year reflects a mix of factors rather than a collapse in the obesity thesis. Concerns centred on manufacturing capacity, slower-than-expected supply expansion, pipeline disappo

🛑 The "Perfect Trade" is a Myth: Why Being Right Once Isn't Enough Remember early 2020? It was a masterclass in market psychology. In February and March, the world seemed to be ending. Stocks plummeted. Panic was everywhere. Yet, by June 8, 2020, the Total US Stock Market (VTI) hadn't just recovered—it was positive by 0.77%. If you blinked, you missed the recovery. And that exposes the most dangerous trap in investing. 📺 The Media’s Survivor Bias During that volatility, headlines loved to celebrate two types of "geniuses":  * The Prophets: Those who sold everything in Jan 2020.  * The Snipers: Those who bought the absolute bottom in March. It makes for a great story. It makes us feel like that is what investing is supposed to be: dodging bullets and timing tops and bottoms. But h

NVO Pops +9%: Is the $149 Oral Pill a Game-Changer or a Desperate Pivot? The GLP-1 Wars just had their "iPhone Moment." For the past year, Novo Nordisk  investors have been living in a nightmare. The stock collapsed -42% from its highs, plagued by supply shortages while rival Eli Lilly ($LLY) executed flawlessly. But last night changed the narrative. The FDA approval of the first oral Wegovy—priced aggressively at $149/month via TrumpRx—isn't just a product launch. It is a fundamental business model shift. NVO is moving from "luxury biotech" to "mass-market consumer goods." The stock jumped +9% post-market. But before you FOMO in, we need to understand: Is this the bottom, or just a dead cat bounce before 2026? 1️⃣ The "Volume Over Margin" Gamble Retail traders often miss the manufact

Silver (XAGUSD) maintains a bullish Elliott Wave structure with pullbacks offering buying opportunities It continues to trade firmly higher and maintains a bullish structure. Price action respects the broader Elliott Wave sequence and keeps favoring the upside while key support levels hold. The rally from the prior swing low remains impulsive and shows no signs of exhaustion yet. From the earlier low, Silver completed a corrective phase and then turned higher in a clear impulsive advance. This move confirms that wave ((ii)) has already ended. Price has since resumed higher within wave ((iii)). Momentum remains strong, which is typical during a third-wave sequence. Within wave ((iii)), Silver is unfolding higher in wave (i). Wave (ii) has already completed as a corrective pullback. Price ha

Tesla Reclaims Its Crown—Is the Market Finally Pricing in the "AI Singularity"? Tesla is officially back in the club. By clawing its way back into the top seven U.S. stocks by market cap, Tesla Motors(TSLA) hasn’t just shuffled the rankings—it has signaled a massive psychological shift. For the last year, Wall Street treated Tesla like a struggling car company facing margin compression. Now, smart money is waking up to the reality we’ve known for a while: Tesla is an optionality machine. With the legal reinstatement of Elon Musk’s 2018 compensation package, the biggest overhang on the stock has evaporated. But the real story isn't just about Musk getting paid; it's about the market finally granting Tesla the "AI Premium" it deserves. Here is why I am staying decisively bullish, and why I b

Gold at $4,500: Why This Is a Structural Shift, Not a Bubble (Target: $5,000?) We are witnessing history in real-time. Gold (XAU/USD) hovering near $4,500 isn’t just another resistance test—it is the culmination of nearly 50 record highs this year alone. While retail traders might be screaming "overbought," the price action tells a very different story. With Silver breaking above $70, Platinum and Palladium joining the party, and Gold surprisingly lagging its peers since Jackson Hole, the setup here is screaming "catch-up." This isn't a speculative frenzy; it’s a re-pricing of global fiat credibility. Here is why I believe the path to $5,000 in 2026 is not just hype, but a realistic macro inevitability—and how you should position for it without getting burned by leverage. 1️⃣ This is a Sys

$DBS(D05.SI)$ $OCBC Bank(O39.SI)$ $JPMorgan Chase(JPM)$ $UOB(U11.SI)$ $Singtel(Z74.SI)$ Singapore's banking beasts are on a rampage, with DBS smashing a fresh high of $56.34 today on December 24, 2025, capping a stellar 36% year-to-date surge that's left investors buzzing on wealth-management fees exploding 25% in Q3 and dividend yields locking in 4.2% for that sweet cash flow drip. OCBC's not far behind, hitting $19.47 on balanced growth from insurance arms like Great Eastern premiums up 18% and AUM at $280 billion – this defensive duo's resilience shines bright amid glo

$Dynavax(DVAX)$ $Sanofi SA(SNY)$  $GlaxoSmithKline PLC(GSK)$   🧠 Strategic M&A Meets a High-Conviction Technical Resolution I’m watching $DVAX resolve a multi-year compression exactly the way credible M&A breaks tend to resolve when the market believes the outcome is real. Sanofi has agreed to acquire Dynavax Technologies in an all-cash transaction valuing the company at roughly $2.2B, paying $15.50 per share. That’s a 39% premium to the 23Dec25 close and about a 46% premium to the three-month VWAP. The deal is board-approved, funded entirely with cash, and expected to close in Q1 2026 subject to regulatory approvals. 🧬 Fundamental

A lot of comparisons are starting to be made between $Rocket Lab USA, Inc.(RKLB)$ and space X. But are they really comparable? Let's begin with rockets. Rklb has electron, small lift, dedicated, and precision insertion. Space X has nothing like this. But space x does have starship. while it's still in development, rklb has nothing like it. Starship Does present a major concern though regarding the IPO. Investors want returns. Starship, is a whale with an absolutely insane cash appetite. Going to the moon and mars seem to lack a business case unless government steps in hugely. so while the ipo might rocket initially, I will be assessing the long term impact of the starship strategy once i get some concrete numbers. they both have medium lift rocket